The FDA-approved monoclonal antibody infusion known as donanemab, is showing promise to reduce cognitive decline among early-onset patients.
SEATTLE — An estimated 7.2 million Americans age 65 and older are living with Alzheimer’s disease, according to an extensive 2025 report compiled by the Alzheimer’s Association.
While there is still no cure, doctors at UW Medicine are hopeful about a second new medication being offered in Seattle that could be a game changer in managing the disease.
It’s called donanemab.
“It’s a new drug that patients with early-stage Alzheimer’s disease will have access to,” said Dr. Michael Rosenbloom, an associate professor of neurology at
→ Continue reading at King 5
